Navigation Links
Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC
Date:5/21/2013

Raleigh, NC (PRWEB) May 21, 2013

Clinverse, Inc., a global technology and financial services company for clinical trials, announced today it has formed a strategic alliance with Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical commerce platform aggregates data collected through an automated investigator payment process. SpendMD™, Aggregate Spend Solutions’ recently-launched flagship product, is the only complete solution for tracking and reporting transfer of value at investigator meetings or any meeting where healthcare providers (HCPs) receive varying types of compensation from sponsors in exchange for their involvement. Together, the combined solution provides a “one-stop-shop” for the collection of data required by the Sunshine Act, also known as the Physician Payment Sunshine Act (PPSA).

“We are pleased to announce this strategic partnership with SpendMD. Not only are we able to provide our clients with the ability to collect investigator payment data currently generated by ClinPay FLS, but we are now able to automate the acquisition of investigator payment data collected during investigator meetings and other sponsor-related events,” said Steve Ayala, Clinverse President and head of partnerships. “We know that compliance with the Sunshine Act requirements have been, and continue to be, a significant concern for our clients and the industry as a whole. We are investing our resources, time and expertise to develop integrated solutions to address these concerns through the automation of the data collection and reporting process required by CMS.”

ClinPay FLS’ open application programming interface (API) allows for seamless integration with SpendMD, as well as other clinical trial platforms (e.g., EDS, CTMS, and IxRS applications), meeting planning software, or any other electronic systems used to accurately report various direct or indirect payments made to HCPs as required by the new legislation. With the Sunshine Act now requiring the collection of data beginning August 1, 2013, the timing of this partnership benefits clinical trial sponsors looking to gain compliance and provide a comprehensive, automated solution for tracking total investigator spend, both direct and indirect, while alleviating a time-intensive burden from sponsors.

John Lewis, CEO of Aggregate Spend Solutions, stated, “We understand the complexities unique to transfer of value spend capture – working with multiple vendors, meeting-related expenses, and other issues. Our partnership with Clinverse allows us to provide our clients with our expertise and proven technology, while also providing them access to a centralized and scalable aggregate spend solution anchored by Clinverse’s proven investigator payment platform. We look forward to working with Clinverse and continuing to provide our clients with all of the services and technology required to meet the Sunshine Act reporting requirements that are looming.”

About Aggregate Spend Solutions, LLC

Aggregate Spend Solutions, LLC was formed as a result of the new and stringent reporting requirements of the Physicians Payment Sunshine Act. SpendMD™, sunshine tracking and reporting is the organization’s key software product that provides the Health and Life Science Industries with the only complete solution for tracking and reporting “indirect spend” for HCP Meetings. Based in Raleigh, North Carolina with global development centers, Aggregate Spend Solutions is a key leader in the design, development, implementation and support of data aggregation products and services. For more information, please visit http://www.spendmd.com.

About Clinverse, Inc.

Clinverse, Inc. is a global technology and financial services company that delivers highly secure, cloud-based financial management and payment solutions for the clinical trials industry. Founded in 2008 and headquartered in Raleigh, NC, the company delivers clinical financial solutions through the only truly collaborative and transparent financial management and payment platform. Used by leading BioPharma companies, Clinverse has developed ClinPay® FLS, a fully-configurable, game-changing SaaS-based platform which manages tens of millions of dollars in financial transactions for thousands of Global sites while supporting payments in 140 different currencies. For more information, please visit http://www.clinverse.com.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10751165.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , ... May 25, 2016 , ... Scientists at the ... options being tried for mesothelioma may be hampering the research that could lead to ... Click here to read it now. , The team evaluated 98 ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Food and Drug Administration (FDA) has granted the company’s orphan drug designation request ... second orphan drug designation granted by the FDA. , Spinocerebellar ataxia is ...
(Date:5/24/2016)... ... ... Last week, Callan Capital, an integrated wealth management firm specializing in asset ... Diego Life Science event at the Estancia La Jolla Resort and Spa. , Over ... Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former CEO ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® ... Farming in 2017 and Beyond. The paper outlines the key trends that are ... industry. , “We’ve witnessed a lot of highs and lows as the precision ...
Breaking Biology Technology:
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):